Hikal Limited (HIKAL) fundamentals
Hikal Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as HIKAL (ISIN INE475B01022). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Hikal Limited does
Hikal Limited is an India-based company, which is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Pharmaceuticals segment produces active pharmaceutical ingredients. Its facilities are in Jigani, Bangalore and Panoli, Gujrat. The Crop protection segment produces pesticides and herbicides. Its facilities are in Taloja, Mahad, Maharashtra and Panoli, Gujarat. Its human health product categories include anti-convulsant, anti-emetic, anti-histaminic, anti-depressant, anti-psychotic, anti-lipemic, and hemorheologic. Its animal health product categories include anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, and NSAID. Its crop protection products are used in algaecide, biocide, fungicide, herbicide, insecticide, and intermediate. It offers contract research services for synthesis, process development, and manufacturing projects.
Valuation and market data
| Last close | ₹234.78 |
|---|---|
| Market capitalisation | ₹2,896 crore |
| Enterprise value | ₹3,364 crore |
| P/E (TTM) | 0.00 |
| Price to book | 2.29 |
| Price to sales (TTM) | 1.66 |
| Book value per share | ₹102.32 |
| Dividend yield | 25.56% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Feb 14 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹1,725 crore | ₹-78 crore | ₹-49 crore | 0.00 |
| Mar 2025 | ₹1,865 crore | ₹124 crore | ₹91 crore | 7.37 |
| Mar 2024 | ₹1,787 crore | ₹95 crore | ₹70 crore | 5.64 |
| Mar 2023 | ₹2,028 crore | ₹105 crore | ₹78 crore | 6.36 |
| Mar 2022 | ₹1,948 crore | ₹219 crore | ₹161 crore | 13.02 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 68.8% |
|---|---|
| Foreign institutions (FII) | 1.0% |
| Mutual funds | 5.9% |
| Other domestic institutions | 1.3% |
| Retail and others | 22.9% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.